Showing results (11-20 of 351) with videos related to
Sort By:
Pageof 36
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2010
Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculataShuo Yang, Andrew M Evens, Sheila Prachand, et al.American Journal of Clinical Pathology|July 16, 2011
Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-γδ T-cell large granular lymphocytic leukemiaYi-Hua Chen, Amy Chadburn, Andrew M Evens, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cellsSavita Bhalla, Sriram Balasubramanian, Kevin David, et al.British Journal of Haematology|April 26, 2014
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II studyAndrew M Evens, Mitchell R Smith, Izidore S Lossos, et al.Blood|September 25, 2004
Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cellsAndrew M Evens, Philip Lecane, Darren Magda, et al.Current Opinion in Oncology|January 1, 2005
Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancerAndrew M EvensHematological Oncology|June 15, 2025
Newly Diagnosed Classical Hodgkin Lymphoma: Optimizing Outcomes in a New Therapeutic EraAndrew M EvensJournal of the National Comprehensive Cancer Network : JNCCN|May 19, 2017
Strategies for Management of Relapsed or Refractory Hodgkin LymphomaLeo I GordonSeminars in Oncology|January 8, 2004
Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)Leo I GordonLeukemia & Lymphoma|August 22, 2012
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidationRupali Roy, Andrew M Evens, David Patton, et al.Pageof 36